Post-trial follow-up | Adjuvant Olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer.
17 Oct, 2022 | 12:27h | UTCOriginal Study: Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
OS from #OlympiA now out on Annals. After 3.5y of f-up, pts receiving adjuvant olaparib derived a significant OS benefit (4y Δ 3.4%, 89.8% vs 86.4%). No increased risk of MDS/AML with olaparib. Important to test for BRCA in potentially eligible patients.https://t.co/ygkr0cOwF0 pic.twitter.com/bg4Y2yyXwZ
— Paolo Tarantino (@PTarantinoMD) October 11, 2022
Images under a Creative Commons Attribution (CC BY 4.0) license